Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-01-26 Purchase |
2023-01-31 3:42 pm |
GENELUX CORP | GNLX | Zhang Qian Associate VP, Research |
200 | $6.2485 | $1,250 | 133,533 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-02-17 Option Award |
2023-05-02 4:26 pm |
N/A N/A |
GENELUX CORP | GNLX | Zhang Qian Associate VP, Research |
6,000 | $0 | 139,533 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:25 pm |
N/A N/A |
GENELUX CORP | GNLX | Ryder Sean General Counsel |
900 | $0 | 900 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:23 pm |
N/A N/A |
GENELUX CORP | GNLX | Samuelson Doug Chief Financial Officer |
3,600 | $0 | 3,600 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:22 pm |
N/A N/A |
GENELUX CORP | GNLX | Yu Tony VP, Clinical Trial Operations |
9,000 | $0 | 159,000 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:21 pm |
N/A N/A |
GENELUX CORP | GNLX | Cappello Joseph VP, Pharmaceutical Development |
9,000 | $0 | 9,000 (Direct) |
View |
| 2023-01-30 Conversion |
2023-01-30 4:29 pm |
N/A N/A |
GENELUX CORP | GNLX | Szalay Aladar 10% Owner |
3,500,000 | $0 | 2,341,238 (Indirect) |
View |
| 2023-01-30 Conversion |
2023-01-30 4:28 pm |
N/A N/A |
GENELUX CORP | GNLX | Thomas John Director |
1,880,000 | $0 | 470,000 (Direct) |
View |
| 2023-01-30 Conversion |
2023-01-30 4:25 pm |
N/A N/A |
GENELUX CORP | GNLX | Woodward Gabe Director |
37,362 | $0 | 5,984 (Indirect) |
View |
Ownership |
2023-01-25 7:33 pm |
N/A N/A |
GENELUX CORP | GNLX | Szalay Aladar 10% Owner |
0 | $0 | 4,599,998 (Direct) |
View |
Ownership |
2023-01-25 7:31 pm |
N/A 2032-09-08 |
GENELUX CORP | GNLX | Mirabelli Mary Director |
0 | $0 | 25,000 (Direct) |
View |
Ownership |
2023-01-25 7:30 pm |
N/A N/A |
GENELUX CORP | GNLX | Woodward Gabe Director |
0 | $0 | 69,694 (Indirect) |
View |
Ownership |
2023-01-25 7:29 pm |
N/A 2024-06-26 |
GENELUX CORP | GNLX | Tyree James L Director |
0 | $0 | 151,567 (Direct) |
View |
Ownership |
2023-01-25 7:28 pm |
N/A N/A |
GENELUX CORP | GNLX | Thomas John Director |
0 | $0 | 550,740 (Direct) |
View |
Ownership |
2023-01-25 7:27 pm |
N/A 2031-10-03 |
GENELUX CORP | GNLX | Ryder Sean General Counsel |
0 | $0 | 150,000 (Direct) |
View |
Ownership |
2023-01-25 7:26 pm |
N/A 2032-09-08 |
GENELUX CORP | GNLX | Samuelson Doug Chief Financial Officer |
0 | $0 | 88,300 (Direct) |
View |
Ownership |
2023-01-25 7:25 pm |
N/A 2024-11-03 |
GENELUX CORP | GNLX | Scigalla Paul Chief Medical Officer |
0 | $0 | 163,883 (Direct) |
View |
Ownership |
2023-01-25 7:24 pm |
N/A 2025-04-30 |
GENELUX CORP | GNLX | Cappello Joseph VP, Pharmaceutical Development |
0 | $0 | 159,999 (Direct) |
View |
Ownership |
2023-01-25 7:23 pm |
N/A N/A |
GENELUX CORP | GNLX | Yu Tony VP, Clinical Trial Operations |
0 | $0 | 389,653 (Direct) |
View |
Ownership |
2023-01-25 7:22 pm |
N/A N/A |
GENELUX CORP | GNLX | Zhang Qian Associate VP, Research |
0 | $0 | 372,986 (Direct) |
View |
Ownership |
2023-01-25 7:21 pm |
N/A 2024-08-14 |
GENELUX CORP | GNLX | Zindrick Thomas President and CEO |
0 | $0 | 1,439,273 (Direct) |
View |